Citadel Advisors
SWTX

Citadel Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Citadel Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,600
Closed -$1.72M – 14067
2025
Q2 		$1.72M Sell
36,600
-248,600
-87% -$11.1M ﹤0.01% 5991
2025
Q1 		$12.6M Buy
285,200
+224,300
+368% +$10.3M ﹤0.01% 2565
2024
Q4 		$2.2M Buy
60,900
+27,600
+83% +$964K ﹤0.01% 5430
2024
Q3 		$1.07M Sell
33,300
-6,600
-17% -$247K ﹤0.01% 6747
2024
Q2 		$1.5M Buy
39,900
+30,500
+324% +$1.28M ﹤0.01% 5841
2024
Q1 		$463K Sell
9,400
-28,700
-75% -$1.33M ﹤0.01% 8564
2023
Q4 		$1.39M Buy
38,100
+33,400
+711% +$872K ﹤0.01% 6027
2023
Q3 		$109K Sell
4,700
-4,500
-49% -$123K ﹤0.01% 10789
2023
Q2 		$241K Buy
9,200
+4,900
+114% +$129K ﹤0.01% 9486
2023
Q1 		$111K Hold
4,300
– – ﹤0.01% 11108
2022
Q4 		$112K Sell
4,300
-27,200
-86% -$670K ﹤0.01% 11057
2022
Q3 		$899K Sell
31,500
-2,800
-8% -$80.3K ﹤0.01% 7224
2022
Q2 		$844K Buy
34,300
+15,500
+82% +$567K ﹤0.01% 7426
2022
Q1 		$1.06M Buy
+18,800
New +$1.08M ﹤0.01% 7550

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's SWTX Position: Q3 2025 in Review

Citadel Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 74,505 shares — an estimated $3.5M sold.

Citadel Advisors first reported a position in SWTX in Q3 2019 and held it in 24 quarters. The position peaked at $66.9M in Q2 2021. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Citadel Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 74,505 SpringWorks Therapeutics shares in Q3 2025, an estimated $3.5M.
  • Citadel Advisors first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 24 quarters.
  • Citadel Advisors's SpringWorks Therapeutics position peaked at $66.9M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.